Abstract:Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor monotherapy in germline BRCA1 and BRCA2 mutation-associated metastatic breast cancer is a well-tolerated and an effective therapeutic strategy, however, the durability of response can be limited. Checkpoint inhibitors targeting the PD-1/PD-L1 axis as monotherapy in metastatic triple-negative breast cancer (mTNBC) have a limited role due to low response rates, but are capable of long, durable responses. Combination PARP inhibition with checkpoint blockade is an emerging area of investigation with potential synergy to produce robust responses with durability. Mechanistically, PARP inhibition activates the stimulator of interferon gene (STING) pathway to promote dendritic cell and T lymphocyte recruitment, increases tumor neoantigens, and upregulates PD-L1 expression to increase the immunogenicity of the tumor and thereby potentially enhance responses to immunotherapy. Several clinical trials have reported early results on PARP inhibitor and PD-1/PD-L1 checkpoint inhibitor combinations. All studies have shown safety and tolerability of this combination regimen. In advanced breast cancer associated with a germline BRCA1 or BRCA2 mutation, response rates have been high and similar to what is observed with PARP inhibitor monotherapy. Additional follow-up is needed to see if combination with a checkpoint inhibitor can lead to a clinically meaningful extension of durability of response in patients with germline mutations in BRCA1 and BRCA2 . In unselected mTNBC in the 1st–3rd line setting, response rates of combined PARP inhibitor and PD-1/PD-L1 inhibitors have ranged from 18–21%, with higher rates of response among those with alterations in homologous recombination DNA repair pathway genes. Multiple ongoing studies will report additional data on combinations of PARP inhibitors and checkpoint blockade in the future and this combination strategy remains an active area of investigation.

Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results

Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications

Targeting PARP for the Optimal Immunotherapy Efficiency in Gynecologic Malignancies

Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer

Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer

Advances in research of PARP inhibitors in combination with chemotherapeutic agents in the treatment of malignant tumors

PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer

Combating Tumor PARP Inhibitor Resistance: Combination Treatments, Nanotechnology, and Other Potential Strategies

Focus in Ovarian Cancer

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies

Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy

PARP Inhibitors As Antitumor Agents: a Patent Update (2013-2015)

Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization

Combining PD-1/PD-L1 inhibitor and PARP inhibitor: a new perspective on the treatment of triple negative breast cancer

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions